Public Release: 

ECCO 14 -- The European Cancer Conference

Media invitation

ECCO-the European CanCer Organisation

Come to Europe's premier cancer conference and hear about new research on the entire spectrum of cancer from basic science and translational research, to prevention, treatment, nursing and supportive care for all types of tumours.

In more than 1,300 presentations from scientists working in 75 countries, the conference will discuss the latest advances in stem cell research, proteomics, biomarkers, pharmacogenomics, imaging, treatment and survivorship, as well as the latest evidence on epidemiological trends, complementary therapies, quality of life issues and the influence of lifestyle choices on the development and outcome of cancer. The programme includes more new results from phase III clinical trials than ever before.

The Federation of European Cancer Societies (FECS) welcome the interest of the press in cancer issues and is happy to provide full assistance to journalists attending ECCO 14, or using the conference website as a resource in their coverage of cancer issues. A media centre with computing, fax, photocopying and free international phone and internet connections will be available. English, Spanish and French-speaking press officers will be on hand to assist you.

NB: the official language of ECCO 14 is English but press materials will be in English and Spanish. There will be news briefings on Monday, Tuesday, Wednesday and Thursday, with an extra Spanish-language news briefing on Monday afternoon.

Here is a sample of the new results to be announced at the conference (embargoed to time of presentation at ECCO 14):

  • Discovery of gene with widespread involvement in stimulating tumour growth holds out promise for treating many common cancers

  • Quality of life after endometrial cancer treatment can be significantly improved by the use of internal rather than external radiotherapy

  • Identification of molecular fingerprint for resistance to commonly used chemotherapy drug can predict response to treatment in breast cancer

  • Clinical Trials Directive responsible for significant drop in academic clinical research across Europe

  • Tumour cells circulating in blood can predict which patients are likely to have a recurrence of cancer after chemotherapy treatment

  • Tackling ageist attitudes and skills gaps are among the challenges in planning for cancer care in 2020

  • Breast cancer susceptibility gene predicts outcome and response to treatment in lung cancer

  • Improved treatment for difficult childhood brainstem gliomas

  • First molecular profiling of colon cancer patients accurately predicts survival

  • Survey reveals ignorance and confusion about cancer among the elderly

  • Researchers discover a specific genetic mutation can double or treble a woman's risk of ovarian cancer

  • Researchers discover PET is more useful than mammography or ultrasound in detecting a tumour's response to chemotherapy and the patient's likelihood of survival

  • Study of 70,000 women reveals whether wine, beer or spirits are most likely to trigger the onset of breast cancer, or whether they are all as bad as each other

  • post traumatic stress symptoms in adolescent children of cancer patients - do their parents realise?

  • study fuels debate over whether body size and exercise influence ovarian cancer risk

  • Chemotherapy drug delays progression of operable pancreatic cancer

  • Married oesophageal cancer patients fare worse than their single counterparts in some aspects of quality of life

  • Experimental drug shows promise advanced kidney cancer patients whose options run out after their tumour fails to respond to the cutting edge therapy

  • Progress reported in zoning in on biomarkers for better colon cancer treatment

  • Study offers reassurance to women worried about whether pregnancy will affect cancer survival

  • Couples more likely to divorce if one partner is diagnosed with certain types of cancer

  • New type of drug shows promise in tackling melanoma in innovative way.

Registration (media only)

ECCO 14 is open to bona fide representatives of print and electronic media and healthcare media. Registration is free of charge to journalists who are in possession of a valid, recognised press card. Freelance journalists must present a commissioning letter on headed paper from a recognised news organisation or publication.

A copy of the Press Card or of the commissioning letter should be sent, together with the media registration form (which can be downloaded from the FECS website at to: Riitta Kettunen: (with scanned documents) or by fax to +32 (0)2 775 0200.

The original of the Press card or of the commissioning letter will also have to be presented at the conference registration desk together with a valid passport or ID-card.

Journalists must register in person. Applications for media registration made via pharmaceutical, marketing or public relations companies will not be considered.

Media registration in advance is strongly recommended.

You may register on site providing that you produce official press credentials. (Business cards are NOT acceptable).

Hotel accommodation (media only)

Hotel rooms can be booked on the FECS website at:

Or you can contact the accommodation agent directly:
Viajes Iberia Congresos (VIC)
Fontanella 21-23 (4 - 1a)
08010 Barcelona
Telephone: +34 (93) 510 10 05
Fax: +34 (93) 510 10 09

Any enquiries about registration and hotel accommodation for non-media should be directed to the FECS office (, NOT to Emma or Mary.

NB: hotel rooms will go very quickly so early booking is recommended.


If you have any questions (media only), contact: Emma Mason, ECCO 14 media consultant, tel: +44 (0)1376 563090, mobile: +44 (0)7711 296 986, email: or Mary Rice, FECS media consultant, tel: +32 (0)2 770 0407, mobile: +44 (0)780 304 8897, email:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.